Clinical Trial Update: Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD) [Phase 4]

View source ↗

Summary

This Phase 4 trial evaluated the safety and effectiveness of intravitreal injections of brolucizumab for neovascular age-related macular degeneration, with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Brolucizumab (brolucizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Neovascular Age-related Macular Degeneration (nAMD) | Phase 4 | Status: COMPLETED | Results posted: 2024-12-10